Chaoju Eye Care Holdings Limited provided consolidated earning guidance for the six months ended June 30, 2023. For the period, the Group expects to record a revenue in the range of RMB 670 million to RMB 720 million for the six months ended June 30, 2023, representing an increase of approximately 26% to 35%, as compared to a revenue of RMB 532.7 million for the corresponding period in 2022; and a net profit in the range of RMB 140 million to RMB 155 million for the six months ended June 30, 2023, representing an increase of approximately 38% to 52%, as compared to a net profit of RMB101.8 million for the corresponding period in 2022. Based on information currently available, the Board considers that such expected increases are primarily attributable to, among other things, the following reasons: (i) the recovery of demand for opthalmic services, owing to the increased corporate efficiency which enhanced the Group's reception capacity for patient visits, the recovery of the industry and the general economic environment in the PRC after the COVID-19 pandemic, which led to an overall increase of the Group's revenue; and (ii) the growth in net profit due to higher gross profit margin resulted from the expansion of consumer opthalmic services and basic opthalmic services businesses after the COVID-19 pandemic as well as better economies of scale so derived.